BFRI
BEARISH
$0.86
Live
Biofrontera Inc. · NASDAQ
Target $6.0
(+601.3%)
$0.54
52W Range
$1.19
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Mar 20, 2026
Market cap
$9.97M
P/E
N/A
ROE
-1191.7%
Profit margin
-47.3%
Debt/Equity
N/A
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
92%
BFRI exhibits severe financial distress, reflected in a Piotroski F-Score of 1/9 (indicating weak financial health) and a lack of Altman Z-Score data, which raises red flags for potential bankruptcy risk. The company reports massive losses with a -47.28% profit margin, negative ROE (-1191.73%), and declining revenue (YoY -22.50%). Despite a strong gross margin (64.41%), operational inefficiencies and negative cash flows undermine sustainability. The stock trades at a deep discount (Price/Sales: 0.27), but this is not a value signal—rather, it reflects deteriorating fundamentals and investor skepticism. Analysts' 'strong_buy' recommendation appears disconnected from the underlying data.
Key Strengths
High gross margin (64.41%) suggests potential pricing power or low production costs
Recent 1-month price increase (+3.1%) indicates short-term momentum
Analyst consensus is 'strong_buy' despite poor fundamentals, suggesting potential catalyst expectations
Low market cap ($0.01B) may attract speculative interest
Positive surprise in Q1 2024 (actual vs. estimate: +13.4%) shows occasional outperformance
Key Risks
Piotroski F-Score of 1/9 indicates extreme financial weakness and poor operational performance
Negative ROE (-1191.73%) and ROA (-64.91%) signal severe capital inefficiency and loss of shareholder value
Consistent earnings misses in the last 4 quarters (0/4 beats, average surprise -88.35%) reflect deteriorating execution
No free cash flow or operating cash flow data available, raising liquidity concerns
Debt/Equity and total debt/cash not available, but low current ratio (1.15) and quick ratio (0.51) suggest weak short-term solvency
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
16
Weak
35
20
15
10
0
AI Verdict
High Risk
Key drivers: Piotroski F-Score of 1/9, Negative ROE and ROA, Declining revenue and earnings, No available cash flow or debt metrics, Analyst recommendation contradicts fundamental data
Confidence
90%
Value
35/100
Ref P/E, PEG, Graham Number
Positives
- Price/Sales of 0.27 is extremely low
- Current price ($0.86) is below 52-week low ($0.54) and high ($1.19)
Watchpoints
- No Graham Number or intrinsic value due to negative earnings and no growth stability
- Price/Sales discount is not justified by profitability or cash flow
- High risk of delisting or capital raise due to financial distress
Future
20/100
Ref Growth rates
Positives
- Analyst target price of $6.00 implies 600% upside
- Recent Q/Q EPS growth of +29.6% (though based on negative base)
Watchpoints
- Revenue growth is -22.50% YoY
- Forward P/E of -3.72 indicates no earnings in near term
- No positive trend in earnings or cash flow
Past
15/100
Ref Historical trends
Positives
- Some quarters show positive earnings surprises (e.g., Q1 2024: +13.4%)
- Historical EPS has shown volatility but occasional improvement
Watchpoints
- 17 consecutive quarters of losses with worsening actuals
- Average earnings surprise of -88.35% in last 4 quarters
- 5-year price decline of -99.0% reflects long-term deterioration
Health
10/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Current ratio of 1.15 suggests minimal liquidity buffer
- Gross margin remains positive (64.41%)
Watchpoints
- Piotroski F-Score of 1/9 indicates severe financial distress
- No Altman Z-Score available, but low ratios and negative ROE suggest distress risk
- Negative ROE and ROA indicate capital destruction
- No available debt or cash data, but quick ratio of 0.51 is concerning
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend yield or payout ratio
- Dividend strength is 0/100
- Negative earnings make dividend payment impossible
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$0.86
Analyst Target
$6.0
Upside/Downside
+601.3%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for BFRI and closest competitors.
Updated 2026-03-19
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
BFRI
Biofrontera Inc.
Primary
|
-99.0% | -93.2% | -14.4% | -1.0% | +3.1% | -1.7% |
|
NXL
Nexalin Technology, Inc.
Peer
|
-77.4% | -35.6% | -70.6% | -64.9% | +25.1% | +45.4% |
|
XWEL
XWELL, Inc.
Peer
|
-96.0% | -79.6% | +48.0% | +18.8% | -15.6% | +9.6% |
|
TNON
Tenon Medical, Inc.
Peer
|
-100.0% | -99.5% | -28.8% | -37.7% | -0.6% | -2.7% |
|
SINT
Sintx Technologies, Inc.
Peer
|
-100.0% | -99.3% | +53.7% | -32.1% | +1.1% | +0.4% |
BFR
Biofrontera Inc.
Primary
5Y
-99.0%
3Y
-93.2%
1Y
-14.4%
6M
-1.0%
1M
+3.1%
1W
-1.7%
NXL
Nexalin Technology, Inc.
Peer
5Y
-77.4%
3Y
-35.6%
1Y
-70.6%
6M
-64.9%
1M
+25.1%
1W
+45.4%
XWE
XWELL, Inc.
Peer
5Y
-96.0%
3Y
-79.6%
1Y
+48.0%
6M
+18.8%
1M
-15.6%
1W
+9.6%
TNO
Tenon Medical, Inc.
Peer
5Y
-100.0%
3Y
-99.5%
1Y
-28.8%
6M
-37.7%
1M
-0.6%
1W
-2.7%
SIN
Sintx Technologies, Inc.
Peer
5Y
-100.0%
3Y
-99.3%
1Y
+53.7%
6M
-32.1%
1M
+1.1%
1W
+0.4%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-3.72
PEG Ratio
N/A
P/B Ratio
-3.85
P/S Ratio
0.27
EV/Revenue
0.31
EV/EBITDA
-0.65
Market Cap
$9.97M
Profitability
Profit margins and return metrics
Profit Margin
-47.28%
Operating Margin
-89.84%
Gross Margin
64.41%
ROE
-1191.73%
ROA
-64.91%
Growth
Revenue and earnings growth rates
Revenue Growth
-22.5%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
N/A
Current Ratio
1.15
Good
Quick Ratio
0.51
Poor
Cash/Share
$0.29
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q3 2025
Revenue
$0.0B
Gross Margin
70.7%
Op. Margin
-89.8%
Net Margin
-95.1%
Total Assets
$0.0B
Liabilities
$0.0B
Equity
$-0.0B
Debt/Equity
-6.97x
Operating CF
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
100%
Quarterly Earnings History
EPS performance vs analyst estimates
2025-11-12
$-0.57
-1.6% surprise
2025-08-13
$-0.57
-45.1% surprise
2025-05-15
$-0.51
-75.3% surprise
2025-03-21
$-0.23
-231.4% surprise
Healthcare Sector Comparison
Comparing BFRI against 560 companies in the Healthcare sector
(34 bullish, 167 neutral, 359 bearish)
Return on Equity (ROE)
-1191.73%
This Stock
vs
-88.14%
Sector Avg
+1252.1%
(Excellent)
Profit Margin
-47.28%
This Stock
vs
-16.28%
Sector Avg
+190.4%
(Superior)
Revenue Growth
-22.5%
This Stock
vs
124.04%
Sector Avg
-118.1%
(Slower)
Current Ratio
1.15
This Stock
vs
4.47
Sector Avg
-74.3%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
BFRI
Biofrontera Inc.
|
BEARISH | $9.97M | - | -1191.7% | -47.3% | $0.86 | |
|
NXL
Nexalin Technology, Inc.
|
BEARISH | $10.48M | - | -221.5% | -% | $0.51 | Compare |
|
XWEL
XWELL, Inc.
|
BEARISH | $9.04M | - | -% | -58.2% | $1.14 | Compare |
|
TNON
Tenon Medical, Inc.
|
BEARISH | $9.01M | - | -228.1% | -% | $0.8 | Compare |
|
SINT
Sintx Technologies, Inc.
|
BEARISH | $11.09M | - | -303.8% | -% | $2.69 | Compare |
BFRI
Biofrontera Inc.
BEARISH
Mkt Cap
$10M
P/E
-
ROE
-1191.7%
Price
$0.86
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-05 | LUEBBERT HERMANN | Chief Executive Officer | Stock Award | 137,500 | - |
| 2026-03-05 | LEFFLER EUGENE FREDERICK | Chief Financial Officer | Stock Award | 87,500 | - |
LUEBBERT HERMANN
Chief Executive Officer
2026-03-05
137,500 shares
LEFFLER EUGENE FREDERICK
Chief Financial Officer
2026-03-05
87,500 shares
Insider transactions can signal confidence or concerns about company prospects
Past News Coverage
Recent headlines mentioning BFRI from our newsroom.
Newest → oldest
No matching news yet.